Articles tagged with Breast Cancer Cells
Researchers studied how modern immunotherapeutic anti-cancer drugs interact with the immune system, finding that tiny molecular motions are key to their effectiveness. The study, published in Cancers, reveals how these drugs bind to specific receptors on killer cells without activating them.
Researchers discovered that cancer cells with an abnormal number of chromosomes (aneuploidy) are more sensitive to inhibition of the mitotic checkpoint, a cellular mechanism that ensures proper chromosome separation during cell division. This finding has important implications for personalized cancer medicine and drug discovery.
Researchers discovered that aneuploid cancer cells demonstrate heightened sensitivity to damage to the mitotic checkpoint, making them more susceptible to treatment. The study's findings suggest that using aneuploidy as a biological marker could help identify patients who will respond better to certain drugs.
A TGen-led study has developed a test to detect infinitesimally small breast cancer biomarkers in blood samples, improving detection accuracy. The test uses a highly specific protein signature to identify the earliest stages of breast cancer with no false positives.
Researchers at UT Southwestern Medical Center have discovered that removing a key gene called Cbl-b can revitalize exhausted CD8+ T cells to combat malignant tumors. This breakthrough could offer a new approach to harnessing the body's immune system to fight cancers.
Cancer cells can thrive in hostile environments through metabolic adaptation known as the Warburg Effect. Moffitt researchers found that activation of transcription factor KLF4 allows cells to select for this phenotype, enabling them to survive and thrive in poor conditions.
Researchers have identified a molecular crowbar that enables cancer cells to invade surrounding tissues. Hepsin, normally a glue-like protein, becomes a destructive enzyme when activated by Ras, leading to the breakdown of the basement membrane and cancer cell invasion.
Researchers at NUS found that unedited COPA protein promotes cancer, while edited version suppresses a key molecular signalling pathway. The team is now exploring ways to boost natural RNA editing mechanisms to combat cancer.
A team of UT Southwestern researchers has identified the gene ZMYND8 as being increased in breast cancer conditions and correlating with poor survival rates. The gene regulates DNA stability and inhibits antitumor immunity, but removing or inhibiting it allows lymphocytes to invade tumors and prevent growth.
A study from Johns Hopkins Medicine reveals that exposure to B. fragilis toxin can increase the risk of breast cancer by leaving a lasting impression on cells. Researchers found that breast tissue cells exposed to the toxin retained a long-term memory, leading to tumor growth and metastasis in mice.
A new UCL study found that combining heat treatment with chemotherapy delivered via magnetic nanoparticles killed cancer cells more effectively than chemotherapy alone. The therapy showed synergistic effects, enhancing the effectiveness of both treatments when combined. Heat treatment can reduce side effects by targeting only cancer ce...
Researchers at CSHL have discovered a gene-regulating RNA that contributes to breast cancer metastasis. By targeting this RNA, they found a molecule that can reduce tumor growth and metastases in animal experiments.
A study published in Molecular Cell found that blocking ALC1 enzyme can selectively kill cancer cells with homologous recombination deficiency, offering a potential new treatment option for certain types of breast and ovarian cancers. The researchers also identified ALC1 as a key factor in determining patient survival rates.
A type of immune cell known as regulatory T cells acts as a major driver of breast cancer growth by preventing the accumulation of a specific protein that induces anti-tumor responses. Targeting these cells could lead to improved treatment outcomes for patients.
Researchers combine machine learning with cell engineering to create living medicines that selectively kill cancer cells while leaving normal tissue unscathed. By analyzing massive databases of proteins, they assemble a catalog of combinations that can precisely target tumors, overcoming the limitations of current treatments.
Researchers are exploring unique biomarkers in normal breast tissue of Black women to improve treatment options for aggressive breast cancer. DNA analysis revealed a genetic mutation called duffy, which may contribute to higher breast cancer rates and aggressiveness in Black women.
Researchers have developed a more sensitive way to detect circulating tumor cells (CTCs) in blood, which could help doctors find and treat metastases earlier. Using fluorescence spectrometry, as few as nine breast cancer cells can be detected in 200 μL of buffer solution.
A new University of Colorado Boulder study sheds light on CDK7's role in controlling cell growth and transcription, potentially leading to new therapies for hard-to-treat cancers and rare developmental disorders. The findings suggest that CDK7 inhibitors could have distinct therapeutic advantages and result in more selective and less d...
Researchers are exploring glycans in breast cancer cells to develop an earlier test for breast cancer through liquid biopsies. By identifying unique sugar patterns, the team aims to improve diagnostic accuracy and catch cancers at their earliest stage.
A team of researchers discovered that the mammary basal cell lineage contributes to breast cancer heterogeneity, fueling the outgrowth of multiple aggressive tumor subpopulations. By activating a signaling pathway driven by protein kinase A (PKA), they can limit self-renewal potential and impede metastasis.
A new technique has found extremely high stiffness in tiny regions of aggressive breast cancer tumors, suggesting only a few areas need to stiffen for metastasis to occur. This could lead to improved cancer detection and mapping.
A new study reveals that macrophages play a complex role in cancer spread, with two types - M1 and M2 - exhibiting different behaviors. The research uses advanced technologies to identify a distinct population of macrophage cells that migrate towards cancer cells, promoting tumor growth.
Researchers at the University of Alberta have identified a new precision cancer drug for blood cancers that targets enzymes modifying proteins for cell signalling. The treatment, PCLX-001, has shown promising results in killing various types of cancer cells while leaving non-cancerous cells unharmed.
Researchers at Osaka University developed a unique imaging technique using terahertz light to visualize early-stage breast cancer less than 0.5 mm. The technique boasts an accuracy of approximately 1000 times higher than conventional methods and shows promise for quantitative determination of cancer malignancy.
A new study suggests that controlling two proteins, ANP32E and H2AZ, could prevent cancer by regulating cell division and tumor growth. With high levels of H2AZ found in breast and brain cancers, targeting these proteins may make cancer cells more sensitive to anti-cancer drugs or immune-system attack.
Researchers demonstrate that epithelial cells can induce phenotypic and genotypic changes in HER2-positive breast cancer cells, known as cancer cell redirection. This phenomenon restricts proliferation of tumorigenic cells and shifts gene expression profiles towards a non-tumorigenic epithelial profile.
Researchers discovered a novel mechanical mechanism of metastatic cancer cells responding to varying substrate stiffness. Metastatic breast cancer cells adapt their tension and viscoelasticity to survive in new environments, enabling the development of diagnostic kits and drug-screening tests.
Michigan State University researchers are developing a precision nanotherapy that turns the body's own cells into weapons against breast cancer. The approach targets cancer cells' CD47 protein, which defends against immune cells, and uses ultra-thin carbon tubes to arm immune cells for a covert attack.
Breast and lung cancer cells use the Slit2 protein, normally produced by neurons, to signal their migration. This intricate mechanism enables them to escape primary tumors and spread to other organs. The findings could lead to novel diagnostics and treatments for metastasis.
Researchers at Oxford University have identified a genetic vulnerability in nearly 10% of all breast cancer tumors, which can be exploited to selectively kill cancer cells. The discovery also suggests that the same defect leaves cells entirely reliant on their centrosomes for cell division.
Researchers found a gene that produces high levels of TRIM37 protein controlling centrosomes in breast cancer cells. Using an experimental drug to disrupt proteins making centrioles, they selectively killed cancer cells while leaving healthy cells unharmed.
Researchers found that overexpression of gene BIRC2 makes cancer cells resistant to immunotherapy drugs. The study suggests that BIRC2 could be a key marker for identifying patients who may not respond to immunotherapy, paving the way for personalized treatment approaches.
Research published in Nature Precision Oncology reveals that honeybee venom and its compound melittin rapidly destroy triple-negative and HER2-enriched breast cancer cells. The venom's potency allows for selective cell death with minimal effects on normal cells.
Researchers are developing a novel, noninvasive method to target and kill cancerous cells in breast tissue using nanoparticles and ultrasound. This approach, nanoparticle-mediated histotripsy (NMH), aims to improve the safety of treatment for metastatic breast cancer patients by reducing harsh side effects associated with chemotherapy....
Breast cancer cells can exist in different cellular states, ranging from stem-like cells to more differentiated cells. Researchers identified a complex spectrum of cell states between different tumor types, which can range from stem-cells to 'beginner cells' and more differentiated cells.
A study by Hokkaido University scientists found that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer. High levels of IL-34 were associated with poor prognosis in TNBC patients.
Researchers discovered increased levels of neuroprotein sortilin in pancreatic cancer cells, suggesting it as a potential therapeutic target. Sortilin's expression was found higher in female patients and contributed to invasive properties of pancreatic cancer cells.
A team of researchers has identified four subtypes of cells in triple negative breast cancer that contain promising new therapeutic targets. The study found that one subtype produces molecules that suppress immune cells, which may help cancer cells evade the immune system.
Researchers have discovered genes that facilitate the penetration of cancer cells into the brain, a process that complicates cancer treatment. The study highlights potential targets for therapy, including enzymes and microRNAs involved in disrupting blood-brain barrier integrity.
Breast cancer cells send pro-tumorigenic messages to normal cells through extracellular vesicles, reprogramming mitochondrial function and promoting migration. This process may provide a novel target for disrupting cancer progression.
A rapid and affordable test for breast cancer has been developed to combat delayed diagnoses in developing regions. The compact CytoPAN test uses image cytometry to analyze individual cells, yielding results in under 1 hour and requiring minimal training, making it ideal for resource-limited settings.
Researchers at the University of Cambridge discovered that G-quadruplexes form in regions of DNA rich in guanine, playing a role in transcription and driving tumour growth. The structures are prevalent within genes and genetic regions active in breast cancer cells.
Dr. Tanmay Lele's research focuses on mechanobiology, exploring how cells sense external mechanical forces and generate mechanical forces in cancer. He aims to develop new knowledge of human cancers and their progression, with the goal of improving diagnosis and treatment.
A team of researchers has identified a cellular mechanism that inhibits the signal to proliferate and starves malignant cells, leading to their death. The study uses a sea sponge-derived molecule XeB to block calcium ion transport, impacting cancer cell metabolism and leading to high cell death rates.
Researchers at the University of Arkansas have developed a new nano drug candidate that kills triple negative breast cancer cells. The discovery aims to target breast cancer cells directly, reducing adverse and toxic side effects associated with chemotherapy.
Researchers developed a microfluidic device to study breast cancer cells' invasion process, identifying 244 different genes that enable invasive cells. The tool mimics human tissue environments, offering new avenues for biomarkers and targeted therapies.
Researchers at Cold Spring Harbor Laboratory discovered how breast cancer cells evade the immune system by targeting cross-presenting dendritic cells. The key to this evasion lies in the CCR2 protein, which disrupts dendritic cell maturation when present on tumor cells.
Researchers at Northwestern University have developed a new immunotherapy that extends the survival time of mice with triple-negative breast cancer by 150% and prevents tumor reoccurrence. The therapy, which uses spherical nucleic acids, stimulates an immune response to combat cancer cells.
Researchers discovered that metastatic breast cancer cells can reprogram natural killer (NK) cells to stop killing cancer cells and instead aid in metastasis. This work also identifies new immunotherapy strategies to reverse this reprogramming process, offering a potential way to prevent or reduce breast cancer mortality.
Researchers at Johns Hopkins University School of Medicine discovered that breast cancer cells can alter the function of NK cells to facilitate their spread. The study suggests preventing this reprogramming might stop breast cancer from metastasizing, a major cause of death in breast cancer patients.
Researchers at the University of Alabama at Birmingham found that biomechanical forces in the tumor microenvironment enhance breast cancer cell growth, invasion, and metastasis. The study also discovered that exosome production plays a key role in promoting aggressive tumor growth and inducing immune suppression.
Researchers at KAUST developed a new fluorescent multiplex cell rolling assay (FMCR) to analyze cell adhesion, speeding up the process and enabling analysis of multiple cell types. The technique has applications in studying cellular processes in inflammation or cancer cell metastasis.
Researchers found that a single change in the GRP94 protein causes it to behave abnormally, leading to widespread dysfunction in cells. A new small molecule PU-WS13 has been identified as a potential treatment for cancer and Alzheimer's disease by repairing defects in the defective protein.
Research finds that tumor suppressor p53 influences insulin receptor gene expression in breast cancer cells, with mutant p53 strongly stimulating INSR promoter activity. This study highlights the complex interplay between p53 and the INSR pathway, with implications for breast cancer treatment.
Researchers at USC Viterbi's Mork Family Department of Chemical Engineering and Materials Science have discovered a fatal vulnerability in many cancer cells: their inability to adapt to alternative sugars like galactose. The discovery could lead to new metabolic treatments for cancer, targeting cells with specific genetic mutations.
Researchers at Cornell University have identified a protein called TiPARP that acts as a terminator for several cancer-causing transcription factors, including HIF-1. This discovery establishes TiPARP as a potential tumor suppressor and offers new insights into the mechanisms of cancer growth.
Researchers found that pregnancy reduces breast cancer risk by reprogramming breast cells to tuck away the potent cancer gene cMYC and keep them in a state of pre-senescence. This protective mechanism may provide new insights into future cancer treatment and help identify risk before tumors develop.
Researchers have developed a new combined treatment using a senescence inducer and a senolytic nanoparticle that selectively removes senescent cells, delaying tumor growth and reducing metastasis in aggressive breast cancer. The study provides new therapeutic methodologies to be developed in subsequent stages and clinical trials.
Researchers have identified Creld2 as a key player in the development and growth of aggressive breast cancers. High levels of this protein are found in triple negative breast cancers, which have poor survival rates and are difficult to treat.
Scientists have identified key mechanisms within cells that disrupt breast cancer development when exposed to environmental chemicals. The study provides a roadmap for regulators to identify potential breast carcinogens and develop safer products.